The FDA on August 9, 2023, granted accelerated approval to TALVEY® for adults with Relapsed or Refractory multiple myeloma who have received at least four prior lines of therapy, including a Proteasome Inhibitor, an Immunomodulatory agent, and an anti-CD38 monoclonal antibody. TALVEY® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
